KarmelSonix intends to provide acoustic-based clinical solutions for the non-invasive monitoring and management of cardio-pulmonary conditions. The Company's services are being developed in the field of respiratory medicine and will include diagnosis, monitoring and control of respiratory conditions including asthma, sleep apnea, and emphysema.
The Company's activities were augmented following a shareholders meeting held on the 10th November 2006 of which shareholders approved the acquisition of two companies with complementary technologies, the Israeli based Karmel Medical Acoustics Technologies Limited and Melbourne based PulmoSonix Pty Ltd [ACN 096 917 127] a 100% owned subsidiary of the ASX listed Premier Bionics Limited.
The combining of these acquisitions has advanced KarmelSonix's objective of creating global presence in respiratory medicine. The technologies being developed are intended to be a highly complementary blend of non-invasive pulmonary devices which have strong potential pathways to the market and few regulatory hurdles. The first product is intended to be released to the market in the first quarter of 2007, and is a device for assessing nocturnal asthma at home or in the clinic. A Memorandum of Understanding for its commercial distribution has been entered with a major US/UK international respiratory devices company. Following the release of this first product a further three products are being prepared to be released to the market within 18 months.
Specific target markets for the Company's proposed products relate to patients afflicted with prevalent cardio-pulmonary disorders such as asthma, acute respiratory distress syndrome (ARDS), obstructive sleep apnea (OSA), chronic pulmonary disease (COPD) and restrictive lung diseases.
The product pipeline currently under development covers the entire span of respiratory disease management with products designed for:
the home the clinic the hospital, and; during convalescence and long-term care. Successful developments and marketing of these products is intended to place KarmelSonix as a world leader in non-invasive patient monitoring of respiratory diseases. The concept of combing computerized analysis of naturally occurring breath sounds with sound transmission measurements is intended address many un-met specific clinical needs. The combining of these two companies has also brought together a highly skilled and experienced international commercial and scientific team.
KSX Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
